Inflammatory bowel disease (IBD), is primarily composed of Crohn’s disease (CD) and ulcerative colitis (UC) and affects as many as 1.6 million Americans, with approximately 30,000 new cases diagnosed each year. Both are marked by an abnormal response by the…
Model-informed precision dosing (MIPD) involves modeling and simulation to predict the necessary drug dose for a given patient based on their individual characteristics that are most likely to improve efficacy and/or lower toxicity in comparison to traditional dosing. The standard…
The Institute for Clinical and Economic Review (ICER) systematically reviewed and synthesized existing evidence from clinical studies to assess the comparative clinical effectiveness for targeted immune modulators (TIMs) for moderate-to-severe ulcerative colitis (UC). ICER’s draft scoping document was developed with…
Precision dosing focuses on the individualization of drug treatment regimens based on drug attributes, pharmacokinetic/pharmacodynamic variability, disease state characteristics, and patient-specific factors. This concept of dosing offers the hope of optimizing treatment strategies by taking into account specific factors that…
Therapy with biologics has brought a paradigm shift in the management of inflammatory bowel disease (IBD). Infliximab (IFX) has remained one of the key drugs for therapy in IBD. Despite Infliximab’s therapeutic effects, roughly 10-30% of patients do not respond…
In a recent podcast on Podcasts360, Adam Cheifetz, MD, a cochair of the virtual Interdisciplinary Autoimmune Summit (IAS) 2020, gave an overview of his presentation on how proactive and reactive therapeutic drug monitoring differ. During this podcast, he explains how…
Marla Dubinsky, MD, Discusses Patient Success with Dashboard-Guided Infliximab Induction in Gastroenterology & Endoscopy News Article Baysient’s patented iDose system uses Bayesian models, laboratory data, and demographics to individualize Infliximab dosing, effectively improving inflammatory bowel disease (IBD) patient outcomes. Marla…
For many years, Crohn’s disease and IBD went widely misunderstood and unrecognized. In fact, early doctors could not differentiate between IBD and diarrheal diseases caused by infectious agents. It wasn’t until 1932 that Crohn’s disease was initially described in detail,…
When it comes to drug therapy, there is no one right dose for all patients. Each patient is unique and deserves individual treatments tailored specifically for them. Precision dosing has been shown to have significant benefits by improving patient outcomes,…
Marla Dubinsky, MD, Speaks on Proactive Therapeutic Monitoring During a recent podcast on Podcasts360, Marla Dubinsky, MD, discussed how her research on measuring drug concentrations and anti-drug antibodies along with algorithmic approaches to proactive therapeutic drug monitoring could help patients…
